DNDN: If reduction in risk of death is say 18-20% instead of 22% does the FDA approve it? [/quote] 20% perhaps, 18% no (IMO).
I believe the primary endpoint is overall survival. Are you saying that even if there is a statistically significant increase in overall survival, the FDA will reject Provenge on the ground the difference is not clinically significant, if the hazard ratio is 18%? Or are you saying that if the hazard ratio os only 18%, overall survival won't be statistically significant and the primary endpoint won't be met and therefore the FDA will reject?
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.